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Abstract
The ‘gold standard’ design for three-arm trials refers to trials with an active control
and a placebo control in addition to the experimental treatment group. This trial de-
sign is recommended when being ethically justifiable and it allows the simultaneous
comparison of experimental treatment, active control, and placebo. Parametric testing
methods have been studied plentifully over the past years. However, these methods
often tend to be liberal or conservative when distributional assumptions are not met
particularly with small sample sizes. In this article, we introduce a studentized per-
mutation test for testing non-inferiority and superiority of the experimental treatment
compared to the active control in three-arm trials in the ‘gold standard’ design. The
performance of the studentized permutation test for finite sample sizes is assessed in a
Monte-Carlo simulation study under various parameter constellations. Emphasis is put
on whether the studentized permutation test meets the target significance level. For
comparison purposes, commonly used Wald-type tests are included in the simulation
study. The simulation study shows that the presented studentized permutation test for
assessing non-inferiority in three-arm trials in the ‘gold standard’ design outperforms
its competitors for count data. The methods discussed in this paper are implemented
in the R package ThreeArmedTrials which is available on the comprehensive R archive
network (CRAN).
Keywords: non-inferiority, permutation test, three-arm trial, gold standard design,
Wald-type test
1. Introduction
Clinical trials with the gold standard design include an active reference and a placebo
in addition to an experimental treatment. In various areas in clinical research this design
became increasingly popular [1, 2, 3, 4]. Of particular interest in trials with the gold-
standard design is assessing non-inferiority or superiority of the experimental treatment
compared to the reference treatment. With µE, µR, and µP the parameter of interest
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for the experimental treatment group, the reference treatment group, and the placebo
group, respectively, and smaller parameters µk being desired, the null hypothesis of
non-inferiority and superiority can be defined by
H0 : µP − µE ≤ ∆(µP − µR) vs. H1 : µP − µE > ∆(µP − µR).
Superiority is tested with a margin of ∆ ∈ [1,∞) and non-inferiority with a margin
of ∆ ∈ (0, 1). In case of testing non-inferiority, the hypothesis above is commonly
referred to as the retention of effect hypothesis [5]. This definition of non-inferiority
and superiority assumes that the parameter of the reference group µR is larger than
the parameter of the placebo group µP , that is µR > µP . This assumption can also be
interpreted as assay sensitivity, that is the ability of a clinical trial to distinguish an
effective from an ineffective treatment [6]. In general, testing assay sensitivity might be
required in addition the assessment of non-inferiority or superiority. In this manuscript,
however, we focus on testing the hypothesis H0 for either non-inferiority or superiority.
Testing strategies in the gold standard design have been studied in detail by Koch and
Ro¨hmel [7]. For a detailed discussion of the usage of placebo in clinical trials, we refer
to already existing literature [8, 9, 10].
The retention of effect hypothesis, that is the hypothesis H0 in the case of non-
inferiority, has already been studied for various endpoint scales. Pigeot et al. [11],
Hauschke and Pigeot [12], and Hasler et al. [13] studied the retention of effect hypoth-
esis for normally distributed endpoints. Additionally, the retention of effect hypothesis
has been studied by Kieser and Friede [14] and by Munk et al. [15] for binary data,
Mielke et al. [5] investigated censored exponentially distributed endpoints, and Mu¨tze
et al. [16] for negative binomially distributed responses. Moreover, Mielke and Munk
[17] and Balabdaoui et al. [18] established the maximum-likelihood theory for para-
metric models and a generalization of the retention of effect hypothesis. Munzel [19]
derived a statistical test for the non-parametric equivalent. Kombrink et al. [20] intro-
duced a semiparametric analysis of three-arm trials for censored time-to-event data. A
Bayesian approach to three-arm non-inferiority trials has been proposed by Ghosh et
al. [21].
The distributional assumptions being made for the listed methodology for testing
the retention of effect hypothesis H0 cannot always be assessed, for example when stud-
ies are small or when overdispersion is present. If the assumptions for a parametric test
are not fulfilled, the test is in general either conservative or liberal. Furthermore, likeli-
hood based tests – such as Wald-type or score tests – are in general neither robust nor
efficient when the model is misspecified. These limitations of likelihood based tests can
be bypassed by relying on non-parametric tests (see for example Freitag et al. [22]). One
class of non-parametric tests are studentized permutation tests. Studentized permuta-
tion tests are exact tests if the random variables are exchangeable and if exchangeability
is not given they control the significance level asymptotically in many settings. Stu-
dentized permutation tests do not require the assumption of any specific distribution
resulting in widely applicable and robust tests. Moreover, even though they are asymp-
totic tests, studentized permutation tests are often advantageous for small sample sizes
compared to Wald-type approaches. The general theory of studentized permutation
tests has been studied for non-i.i.d. random variables by Janssen [23]. Studentized
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permutation tests have already been studied for the generalized Behrens-Fischer prob-
lem by Janssen [23], the non-parametric Behrens-Fisher problem with unpaired data
by Neubert and Brunner [24] and with paired data by Konietschke and Pauly [25], for
spatial point patterns by Hahn [26], for randomly right censored data by Brendel et
al. [27], for heteroscedastic two-sample problems by Janssen and Pauls [28], and for
general factorial designs by Pauly et al. [29]. The aim of this manuscript is to establish
a permutation test for non-inferiority and superiority in three-arm trials which does not
require any specific distributional assumption and performs well for small sample sizes.
This article is structured as follows. In Section 2, an example from clinical trials in
multiple sclerosis is discussed. The statistical model and the theory of the studentized
permutation test for the retention of effect hypothesis will be introduced in Section 3.
The finite sample size properties of the studentized permutation test for the hypothesis
H0 are studied by means of simulation studies in Section 4. The article concludes with
a discussion of our findings in Section 5 and proofs of the asymptotic properties of the
studentized permutation test in the appendix.
2. A clinical trial example
In a clinical trial setting, the hypothesis H0 has been studied for endpoints in trials
with asthmatic patients where the considered trial consists of 74 subjects [11]. Other
examples include clinical trials in depression [14, 17, 20] and multiple sclerosis [16]. The
theoretical work about the studentized permutation test in this publication, however,
is motivated by phase II clinical trials in relapsing-remitting multiple sclerosis. Multi-
ple sclerosis is an inflammatory disease of the brain and spinal cord [30]. Relapsing-
remitting multiple sclerosis is a form of multiple sclerosis which is characterized by
sudden worsenings of the symptoms called relapses. Clinical trials, and particularly
phase II studies, in relapsing-remitting multiple sclerosis generally include multiple
treatment arms as well as placebo arms and can be rather small [31]. The number
of subjects per group can be as small as ten subjects [31, 32, 33, 34, 35]. A phase II
trial with active and placebo control in relapsing-remitting multiple sclerosis has be
published by Kappos et al. [36]. Besides the active control arm (intramuscular inter-
feron beta-1a) and the placebo, the trial includes two arms with different doses of the
monoclonal antibody ocrelizumab. The trial aims to assess the safety and efficacy of
ocrelizumab. The primary endpoint was the total number of gadolinium-enhancing T1
lesions. Lesions are the regions in the brain and spinal cord which have been damaged
by the disease. The results of the total number of gadolinium-enhancing T1 lesions are
summarized in Table 1. As Table 1 highlights, the distribution of the lesion is char-
acterized by having high probability of zeros, between 35% and 82.7% in the example,
but also a heavy tail, for instance in the example trial four or more enhanced lesions
occurred between 0% and 35% of all cases depending on the group. In literature it has
been proposed to model the galodinium-enhancing T1 lesions as overdispersed count
data, in particular as negative binomially distributed [37]. Overdispersion refers to the
variance exceeding the mean. In Table 2 the theoretically expected values of a negative
binomial distribution with expectation and variance as in the respective sample are
compared to observed total numbers of lesions. Table 2, however, underlines the un-
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Table 1: Total number of galodinium-enhancing T1 lesions over weeks 12, 16, 20, and
24 [36, Table 2].
Number of lesions Placebo Ocrelizumab 600 mg Ocrelizumab 2000 mg Interferon beta-1a
0 19 (35%) 39 (77%) 43 (82.7%) 25 (49%)
1 6 (11%) 2 (4%) 6 (11.5%) 5 (10%)
2 7 (13%) 6 (6%) 1 (1.9%) 5 (10%)
3 3 (6%) 0 2 (3.8%) 0
≥ 4 19 (35%) 4 (8%) 0 17 (33%)
n 54 51 52 52
Mean 5.5 0.6 0.2 6.9
Standard Deviation 12.5 1.5 0.7 16
Table 2: The expected number of lesions according to a negative binomial distribution
with mean and variances as in the sample compared to the observed total number of
galodinium-enhancing T1 lesions which is shown in brackets.
Number of lesions Placebo Ocrelizumab 600 mg Ocrelizumab 2000 mg Interferon beta-1a
0 28 (19) 38 (39) 46 (43) 26 (25)
1 5 (6) 6 (2) 4 (6) 5 (5)
2 3 (7) 3 (6) 1 (1) 3 (5)
3 2 (3) 2 (0) 1 (3) 2 (0)
≥ 4 16 (19) 2 (4) 0 (0) 16 (17)
certainty concerning the distribution of the total number of galodinium-enhancing T1
lesions. The lesion distribution for the two doses of ocrelizumab and the active control
interferon beta-1a is described well by a negative binomial distribution. In contrast,
the lesion distribution in the case of the placebo is clearly overdispersed but cannot be
approximated accurately using a negative binomial. A similar observation was made
when comparing the number of lesions in the placebo group to a zero-inflated Poisson
distribution. For those cases in which the distribution of the endpoint differs between
groups or where the sample size is too small to accurately assess the distribution, the
studentized permutation test for the hypothesis should be preferred over a parametric
approach.
3. Statistical model and the proposed studentized permutation test
Let the independent real-valued random variables Xk,i with i = 1, . . . , nk and
k = E,R, P model the outcomes under experimental treatment (E), reference treat-
ment (R), and placebo (P). We denote the total sample size by n = nE + nR + nP .
The random variable Xk,i follows a distribution Fk and has finite mean E[Xk,i] = µk,
finite positive variance Var[Xk,i] = σ
2
k > 0, and finite forth moment E[X
4
k,i]. For any
asymptotic consideration throughout this article, we assume that none of the groups
vanishes asymptotically, that is wk = limnk,n→∞ nk/n ∈ (0, 1). The non-inferiority or
superiority hypothesis
H0 : µP − µE ≤ ∆(µP − µR) vs. H1 : µP − µE > ∆(µP − µR)
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origins from defining the margin δ > 0 in the non-inferiority/superiority testing problem
Hδ0 : µE − δ ≥ µR vs. Hδ1 : µE − δ < µR
as the difference of placebo response and the reference treatment response [7]. More
precisely, if the margin is defined as δ = f(µP − µR) with f ∈ (0, 1), the hypothesis H0
is equivalent to the testing problem
Hδ0 : µE − f(µP − µR) ≥ µR vs. Hδ1 : µE − f(µP − µR) < µR.
Substituting f by 1 − ∆ results in the non-inferiority or superiority hypothesis H0
defined above. It should be noted that this hypothesis can be rearranged to
H0 : µE −∆µR + (∆− 1)µP ≥ 0 vs. H1 : µE −∆µR + (∆− 1)µP < 0. (1)
The random vector Xn = (Xn,i)i≤n ∈ Rn is defined as
Xn = (XE,1, . . . , XE,nE , XR,1, . . . , XR,nR , XP,1, . . . , XP,nP )
′ (2)
and P denotes its probability measure. The mean of the random variables in group k =
E,R, P is given by X¯k,·. In order to test the non-inferiority or superiority hypothesis H0,
Wald-type statistics are often considered. Here, the Wald-type statistic Tn is obtained
by substituting the parameters µk in the hypothesis H0 from Equation (1) by the means
X¯k,·, k = E,R, P , and dividing the resulting term by an estimator of its standard
deviation, i.e.
Tn = Tn(Xn) =
√
n
X¯E,· −∆X¯R,· + (∆− 1)X¯P,·
σˆ
. (3)
Here, the variance estimator σˆ2 is defined as
σˆ2 =
σˆ2E
wE
+∆2
σˆ2R
wR
+ (1−∆)2 σˆ
2
P
wP
with the group specific sample variances
σˆ2k =
1
nk − 1
nk∑
i=1
(Xk,i − X¯k,·)2, k = E,R, P.
In the following, we introduce the studentized permutation test which uses the Wald-
type statistic Tn as a test statistic. Let (τ(i))i≤n denote a random variable which is
uniformly distributed on the group Sn of all permutations of the first n natural numbers.
We denote the associated probability measure with P˜. The probability measures P˜ and
P are independent. We will use the notation τn(Xn) = (Xn,τ(1), . . . , Xn,τ(n)) for the
randomly permutated vector Xn. For a given vector Xn, the permutation statistic
refers to the test statistic calculated with the permuted vector τn(Xn). That is, the
permutation statistic is the result obtained by the mapping
(τ(i))i≤n 7→ Tn
(
Xn,τ(1), . . . , Xn,τ(n)
) |Xn.
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Then, for a given significance level α ∈ (0, 1) the studentized permutation test ϕPermn
is the function
ϕPermn (Xn) =
{
1 Tn(Xn) < cn(α)
0 Tn(Xn) ≥ cn(α)
with cn(α) the α-quantile of the permutation distribution which is the largest number
such that the inequality
P˜
(
Tn
(
τn(xn)
)
< cn(α)
)
≤ α
holds. The studentized permutation test ϕPermn is an asymptotically exact test. In
other words, at the boundary of the null hypothesis which is given by the equation
(µP − µE) = ∆(µP − µR), the expected value of the test function ϕPermn with respect
to the probability measure P converges to α, that is
lim
n→∞
EP
[
ϕPermn (Xn)
]
= α. (4)
Equation (4) follows immediately from the convergence of the distribution of the statis-
tic Tn against a normal distribution and the asymptotic normality of the permutation
statistic. Asymptotic normality of the permutation statistic refers to the limit
sup
t∈R
(∣∣∣P˜(Tn (τn (Xn)) < t∣∣Xn)− Φ(t)∣∣∣) P−−−→
n→∞
0. (5)
Put into words, the asymptotic normality of the permutation statistic is the uniform
convergence in P-probability of the cumulative distribution function of the permutation
statistic against the cumulative distribution function Φ of a standard normal distribu-
tion. From the limit in Formula (5) it follows directly that the critical value cn(α) of the
permutation test converges to the α-quantile of a standard normal distribution. The
asymptotic normality of the permutation statistic will be proven in the appendix using
the central limit theorem for conditional permutation distributions [23].
4. Simulation study
The small sample size properties of the studentized permutation test are studied in
this section by means of a Monte-Carlo simulation study.
For comparisons two Wald-type tests, which use the same Wald-type statistic Tn
as the studentized permutation test, are included into the simulation study. The first
Wald-type test rejects the hypothesis H0 if the test statistic Tn is smaller than the α-
quantile qα of a standard normal distribution. This test can be written as the function
φWTnn (Xn) =
{
1 Tn(Xn) < qα
0 Tn(Xn) ≥ qα
.
However, the Wald-type test φWTnn in general only meets the target significance level for
large sample sizes. For small sample sizes, the distribution of the test statistic Tn can
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be approximated by a t-distribution with degrees of freedom calculated by the Welch
approximation [38] as done by Hasler et al. [13], that is
νˆ =
(
1
nE
σˆ2E +
∆2
nR
σˆ2R +
(1−∆)2
nP
σˆ2P
)2
1
n2
E
(nE−1)
σˆ4E +
∆4
n2
R
(nR−1)
σˆ4R +
(1−∆)4
n2
P
(nP−1)
σˆ4P
.
Thus, we define the Wald-type test which rejects the null hypothesis H0 when the test
statistic Tn is smaller than the α-quantile of a t-distribution with degrees of freedom νˆ
, i.e.
φWTtn (Xn) =
{
1 Tn(Xn) < tα,νˆ
0 Tn(Xn) ≥ tα,νˆ
.
Both Wald-type tests φWTnn and φ
WTt
n are included in the simulation study for the
sake of comparison. The performance characteristic of interest in the Monte-Carlo
simulation study is whether the tests meet the target significance level α = 0.025. The
tests’ performance is studied for continuous data in the first part and for count data
in the second part. The continuous data is generated using a normal, lognormal, and
Chi-squared distribution, respectively, and the focus will be on the effect of skewness
and unequal variances on the performance of the tests. For count data, the Poisson and
negative binomial distribution are considered as motivated by the distribution of lesions
counts in clinical trials in multiple sclerosis. Moreover, the simulation study focuses on
the non-inferiority hypothesis for small sample sizes. Each simulated type I error is the
result of 25 000 replications which corresponds to a Monte-Carlo error of less than 0.001
for the significance level α = 0.025. The rejection area of the studentized permutation
test is calculated from 15 000 permutations. The simulations are conducted using the R
computing environment (Version 3.1.2) [39]. Both the permutation test and the Wald-
type tests are implemented in the R-package ThreeArmedTrials which is available on
CRAN.
4.1. Continuous data
In Table 3 the scenarios for the Monte-Carlo simulation study of the non-inferiority
hypothesis tests are listed. The mean µE in the experimental treatment group is given
by µE = ∆µR + (1 −∆)µP . The lognormal distribution has location parameter µ = 0
and scale parameter σ = 1. The Chi-square distribution has two degrees of freedom.
For this simulation study, an observation Xk,i is referred to as lognormal or chi-squared
distributed when it is generated from a standardized lognormal or chi-squared dis-
tributed random. More precisely, let X be a lognormal or Chi-squared distributed
random variable, then the Xk,i is calculated by
Xk,i =
(
X − E[X ]√
Var(X)
)
σk + µk, k = E,R, P.
In Figures 1 and 2 the significance level of the different hypothesis tests is plotted
against the reference group mean µR for the different sample size allocations and distri-
butions. Each frame in the 3x3-grids shows the results for one combination of sample
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Table 3: Scenarios considered in the Monte-Carlo simulation study with continuous
data.
Parameter Values
One-sided significance level α 0.025
Clinical relevance margin ∆ 0.8
Mean µP 5.5
Mean µR 0.5, 1, . . . , 5
Group variances (σ2E , σ
2
R, σ
2
P ) (1,1,1), (1,2,3)
Total sample size n 30
Sample size allocations nE : nR : nP 1:1:1, 2:2:1, 3:2:1
Distributions Normal, Lognormal, Chi-squared
size allocation and distribution. In Figure 1 the group variances are identical and in
Figure 2 the variances are unequal, that is σ2E = 1, σ
2
R = 2, and σ
2
P = 3.
Before we compare the performance of the different tests, it is worth noting that Fig-
ures 1 and 2 show that the Wald-type test φWTtn meets the target significance level
for normally distributed data. This is expected since the test φWTtn is the respective
parametric test for normal data [13]. In practice, however, the distribution is unknown
and to draw conclusions about the general performance of the tests, the comparison
must be made for one sample size allocation across multiple distributions and variance
structures. We begin with the balanced design. The permutation test is on the edge
of being conservative for equal variances and conservative for unequal variances. The
Wald-type test φWTtn tends to be liberal for some scenarios but mostly meets the target
significance level for equal variances. In contrast, the test φWTtn is conservative when
the variances are unequal and the data is lognormally or chi-squared distributed. The
permutation test throughout controls the significance level but is more conservative
than the Wald-type test φWTtn . The Wald-type test φ
WTn
n is either liberal, conserva-
tive, or meets the target significance level depending on the variance structure and
the distribution. The results for the sample size allocation 2:2:1 are qualitatively the
same as for the balanced design. For the sample size allocation 3:2:1, the permutation
test meets the target significance level for equal variances but becomes conservative
for unequal variances when the distribution is skewed. Here, the significance level of
the permutation test is closer to the target than the significance level of the Wald-type
test φWTtn which is conservative, except for normally distributed data. As for the other
allocations, the significance level of the Wald-type test φWTtn can be both deflated and
inflated depending on the scenario.
Concluding, for all considered sample size allocations, the Wald-type test φWTtn with
a t-quantile as the critical value and the permutation test perform similar with respect
to meeting the target significance level. For the few scenarios where the Wald-type test
φWTtn tends to be liberal, the permutation test controls the significance level. The per-
mutation test is the more conservative choice for a balanced design and an unbalanced
design with sample size allocation 2:2:1. For a design with sample size allocation 3:2:1,
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the Wald-type test φWTtn is more conservative than the permutation test. Eventually,
both test can be recommended for continuous data. The Wald-type test φWTnn with a
normal quantile as the critical value should not be considered in practice.
4.2. Count data
In this subsection we present the results of the Monte-Carlo simulation study for
count data. The scenario choices in this subsection were motivated by the exam-
ple about lesion counts in clinical trials in multiple sclerosis presented in Section 2.
Throughout this section, the expected value, which we will refer to as rate, in the
placebo group is chosen to be µP = 5.5. Then, the rate in the reference treatment
group is chosen to be between µR = 0.5 and µR = 5. The rate µE in the experimental
treatment group is calculated by µE = ∆µR + (1 − ∆)µP for the margin ∆ = 0.8.
The group variance is defined as a multiple of the group rate, that is σ2k = κµk with
κ = 1, 3 for k = E,R, P . For κ = 1, the random numbers are generated using a Poisson
distribution. For κ > 1, that is in the case of overdispersion, the random numbers are
generated using a negative binomial distribution which is a two-parameter distribution
with location parameter λ > 0 and shape parameter φ > 0. The expected value and
variance are equal to λ and λ(1 + λφ), respectively. Thus, for a given κ, the shape
parameter is φ = (κ− 1)/λ. The negative binomial distribution converges in distribu-
tion to a Poisson distribution when φ approaches zero. We consider the four sample
size allocations nE : nR : nP = 1:1:1, 2:2:1, 3:2:1 and a total sample size of 60. The
example trial discussed in Section 2 had a larger sample size, however, we choose a
trial size of 60 to also study the tests’ performances for sample sizes of smaller phase
II studies. The scenarios are summarized in Table 4. The results of the Monte-Carlo
Table 4: Scenarios considered in the Monte-Carlo simulation study with count data.
Parameter Values
One-sided significance level α 0.025
Clinical relevance margin ∆ 0.8
Placebo rate µP 5.5
Reference rate µR 0.5, 1, . . . , 5
Group variance σ2k = κµk κ = 1, 3
Total sample size n 60
Sample size allocation nE : nR : nP 1:1:1, 2:2:1, 3:2:1
simulation study are shown in Figure 3. Figure 3 shows that the Wald-type test φWTnn
is liberal for all combinations of sample size allocation and distributions. The Wald-
type test φWTtn is liberal too, except for the allocation 3:2:1. The permutation tests
meets the target significance level for Poisson data. However, the permutation test is
liberal for negative binomial distributed data when the rate µR in the reference group
is small. In these cases, the permutation test is less liberal than the Wald-type test
competitors. For negative binomial distributed data we observe that all tests become
less liberal as the rate µR increases. Next, we study the convergence of the significance
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level of the studentized permutation test and the Wald-type test against the target
significance level for increasing n. Figure 4 plots for scenario (µE , µR, µP ) = (1.9, 1, 5.5)
the significance level of the two tests against the total sample size for the sample size
allocation 1:1:1. Figure 4 shows the convergence of the significance level against the
target for an increasing sample size n for a scenario in which the tests do not meet the
target significance level α = 0.025 for small sample sizes. This graphic highlights that
for the tests a considerable increase of the sample size is required to reach the desired
significance level.
In conclusion, the studentized permutation test should be preferred over the Wald-
type test alternatives when testing the retention of effect hypothesis with (overdis-
persed) count data. Even though the permutation test is liberal in a few scenarios, it
is less liberal than the Wald-type tests in the respective scenarios.
5. Discussion
In this publication, we proposed a studentized permutation test for testing non-
inferiority and superiority in three-arm trials in the ‘gold standard’ design, that is
trials with an experimental treatment, an active control, and a placebo. The studen-
tized permutation test is an asymptotic test which does not require any distributional
assumptions on the data, but only a finite expected value and variance. We compared
the studentized permutation test in a Monte-Carlo simulation study with two Wald-type
tests for normally, lognormally, chi-squared, Poisson, and negative binomial distributed
data with particular emphasis on non-inferiority testing and small sample sizes. For
continuous data, the Wald-type test with a normal quantile as the critical value is not
recommended for application since it is either conservative or liberal. The studentized
permutation test and the Wald-type test with a t-quantile as the critical value have
overall a similar performance for continuous data. For skewed data with unequal group
variances both tests become conservative. For use in practice both the studentized
permutation test and the Wald-type test with a t-quantile can be recommended. De-
pending on the sample size allocation either one can be the more conservative choice.
For count data, the studentized permutation test outperforms the Wald-type test al-
ternatives with respect to meeting the target significance level. When the count data
is overdispersed and the difference between the reference group mean and the placebo
mean becomes larges, all considered test are liberal with the permutation test being
the least liberal among the studied tests. In practice, the studentized permutation test
is recommended to analyze three-arm trials with count data when the sample sizes are
small or no distributional assumptions can be made. This is an important finding be-
cause count endpoints are common in clinical trials. While this work was motivated by
the number of lesions in multiple sclerosis, other count endpoints include the number
of hospitalizations in heart failure [40] and the number of exacerbations in COPD [41].
The adjustment for covariates is used in clinical trials to account for factors which
have an influence on the primary endpoint. Covariates are briefly addressed in ICH
guideline E9 [42] and discussed in detail by the Committee for Proprietary Medicinal
Products (CPMP) [43]. The statistical model considered in this publication does not
allow the adjustments for covariates. Especially under consideration of recently pub-
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lished results for studentized permutation tests in general factorial designs [29], future
work could focus on the extension of the proposed studentized permutation test to
models including covariates.
In this publication non-inferiority of the experimental treatment compared to the
reference has been defined with the retention of effect hypothesis which incorporates the
placebo response into the definition of non-inferiority. Hida and Tango [44] and Stucke
and Kieser [45] proposed a pairwise comparison of the experimental treatment and the
reference to assess non-inferiority in a three-arm trial based on absolute margins. This
pairwise assessment of non-inferiority is then part of a global hypothesis which addi-
tionally assesses superiority of the active treatments to placebo. Future research could
focus on applying studentized permutation tests to the respective global hypothesis in
three-arm trials with non-inferiority defined by pairwise comparison.
Appendix A. Asymptotic normality of the permutation statistic
We will now prove the asymptotic normality of the permutation statistic, that is
sup
t∈R
(∣∣∣P˜ (Tn (τ (Xn)) < t∣∣Xn)− Φ(t)∣∣∣) P−−−→
n→∞
0,
by showing that the random vector Xn and the corresponding permutation statistic
as defined in Section 4 fulfil the conditions of the central limit theorem for conditional
permutation distributions [23, Theorem 3.3]. As preparation for the proof, we note that
the test statistic Tn(Xn) can be written as the linear statistic
∑n
i=1 cn,iXn,i with
cn,i :=
√
nEnRnP
nRnP +∆2nEnP + (∆− 1)2nEnR ×


− 1
nE
i = 1, . . . , nE
∆
nR
i = nE + 1, . . . , nE + nR
1−∆
nP
i = nE + nR + 1, . . . , n
a scheme of regression coefficients for each n ∈ N. Then, according to the central
limit theorem for conditional permutation distributions, the permutation statistic is
asymptotically normally distributed if the following five conditions are fulfilled.
1. For each n ∈ N the sum of the squared regression coefficients and the sum of the
regression coefficients is equal to one and zero, respectively:
n∑
i=1
c2n,i = 1 ∀n ∈ N,
n∑
i=1
cn,i = 0 ∀n ∈ N.
Moreover, the maximum of the sequence (cn,i)i≤n converges to zero:
max
1≤i≤n
|cn,i| n→∞−−−→ 0.
11
2. It holds that
lim inf
n→∞
1
n
n∑
i=1
(Xn,i − X¯n,·)2 > 0 P− a.s.
3. There exists σ˜ > 0 such that
1
σˆ2Perm(τn(Xn))
1
n
n∑
i=1
(Xn,i − X¯n,·)2 P×P˜−−−→
n→∞
σ˜2.
4. For d→∞ it holds:
lim sup
n→∞
1
n
n∑
i=1
(Xn,i − X¯n,·)21[d,∞)
(|Xn,i − X¯n,·|)→ 0 P− a.s.
In the remainder of this section, we show that the studentized permutation test for
the retention of effect hypothesis fulfills conditions 1. to 4. Thereto, without loss of
generality, we assume that the expectation of the average of Xn is equal to zero,
E
[
1
n
n∑
i=1
Xn,i
]
= 0, (A.1)
because the statistic Tn(Xn) is invariant under the same shift for each Xn,i. Of course,
the shift does not effect the variance of the random variables.
1. The sums and the limit can be easily calculated which will not be shown here.
2. With the assumption from Formula (A.1) that the expectation of the average X¯n,·
is zero and the strong law of large numbers, the average X¯n,· converges almost
surely to zero. By means of the continuous mapping theorem, the squared average
X¯2n,· converges almost surely to zero. With the property that the sum of three
sequences of random variables converges almost surely if each of the sequences
converges almost surely as well as with the strong law of large numbers, the
average of the squared random variables converges almost surely:
1
n
n∑
i=1
X2n,i
n→∞−−−→ wE(σ2E + µ2E) + wR(σ2R + µ2R) + wP (σ2P + µ2P ) P-a.s.
The assertion follows with the algebraic formula of the sample variance.
3. We define σ˜ := 1 and prove the convergence
1
σˆ2(τn (Xn))
1
n
n∑
i=1
(Xn,i − X¯n,·)2 n→∞−−−→
P×P˜
1. (A.2)
Thereto, we show that the variance estimators σˆ2(τn (Xn)) and
1
n
∑n
i=1(Xn,i −
X¯n,·)
2 converge in P× P˜-probability to the same limit, that is
wE(σ
2
E + µ
2
E) + wR(σ
2
R + µ
2
R) + wP (σ
2
P + µ
2
P ). (A.3)
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The limit of
1
n
∑n
i=1(Xn,i− X¯n,·)2 follows immediately from the second condition
since we showed P–a.s. convergence which implies P× P˜–a.s. convergence which
in turn implies the convergence in P× P˜ – probability.
To prove the convergence of the variance estimator σˆ2(τn (Xn)), we decompose it
by means of the algebraic formula for the sample variance, that is
σˆ2(τn (Xn)) =Wn,1 −W 2n,2 −W 2n,3 −W 2n,4
with
Wn,1 :=
n∑
i=1
dn,iX
2
n,τ(i), Wn,2 :=
1√
nE
nE∑
i=1
√
dn,iXn,τ(i),
Wn,3 :=
1√
nR
nE+nR+1∑
i=nE+1
√
dn,iXn,τ(i), Wn,4 :=
1√
nP
n∑
i=nE+nR+1
√
dn,iXn,τ(i).
The sequence (dn,i)i≤n is defined as
dn,i :=
nEnRnP
nPnR +∆2nPnR + (∆− 1)2nEnR ×


1
nE(nE−1)
i = 1, . . . , nE
∆2
nR(nR−1)
i = nE + 1, . . . , nE + nR
(∆−1)2
nP (nP−1)
i = nE + nR + 1, . . . , n
.
Here, Xn,τ(i) denotes the i-th entry of the vector τn(Xn). We prove the conver-
gence of the variance estimator σˆ2 (τn (Xn)) by showing that Wn,2,Wn,3, andWn,4
converge in P× P˜–probability to zero as well as that Wn,1 converges to the limit
stated in (A.3). The proofs for the convergence ofWn,2,Wn,3, andWn,4 are similar
and, therefore, we only prove it for Wn,2. Said proof follows next.
Taking into account that Xn,τ(i) and Xn,τ(1) have the same distribution as well
as that with probability 1
n
the random variable Xn,τ(1) is equal to the random
variable Xn,i, i = 1, . . . , n, the expectation EP˜ [Wn,2] is equal to
√
κnEX¯n,·. Thus,
E
P×P˜[Wn,2] = 0 follows immediately from the independence of P and P˜ as well
as the assumption that the average X¯n,· has expectation zero. Let ε > 0 be an
arbitrary real number, by applying Markov’s inequality, we obtain
(P× P˜) (|Wn,2| ≥ ε) ≤ 1
ε2
Var
P×P˜ [Wn,2] .
Due to the independence of P and P˜ and the law of total variance, we obtain
Var
P×P˜ [Wn,2] = EP [VarP˜ [Wn,2]] + VarP [EP˜ [Wn,2]] .
Hence, Wn,2 converges in probability to zero if the expectation EP [VarP˜ [Wn,2]]
and the variance VarP [EP˜ [Wn,2]] converge to zero as n tends to infinity. For the
sake of readability, we define
κ :=
nRnP
(nRnP +∆2nEnP + (∆− 1)2nEnR)nE(nE − 1) .
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With κ = κ(n) ∈ O( 1
n2
), we obtain
lim
n→∞
VarP [EP˜ [Wn,2]] ≤ lim
n→∞
κ
nE
n
max
1≤i≤n
VarP[Xn,i] = 0. (A.4)
Moreover, to prove that the expectation EP [VarP˜ [Wn,2]] converges to zero, we
rearrange the variance Var
P˜
[Wn,2] to
κE
P˜

 nE∑
i,j=1,
i6=j
Xn,τ(i)Xn,τ(j) +
nE∑
i=1
X2n,τ(i)

− κn2EX¯2n,·.
For i 6= j and i′ 6= j′, the random variables Xn,τ(i)Xn,τ(j) and Xn,τ(i′)Xn,τ(j′) are
identically distributed with respect to P˜ and with probability 1/(n(n − 1)) the
random variable Xn,τ(1)Xn,τ(2) is equal to Xn,iXn,j. Thus, we obtain
Var
P˜
[Wn,2] =κ
nE(n− nE)
n(n− 1)
n∑
i=1
(Xn,i − X¯n,·)2.
We already proved that the sample variance converges P almost surely and with
k = k(n) ∈ O(1/n2), it follows that the expectation EP[VarP˜ [Wn,2]] converges to
zero as n approaches infinity. Thus, Wn,2 and analogously Wn,3 as well as Wn,4
converge in P× P˜-probability to zero.
To prove the convergence of the variance estimator σˆ2Perm (τn(Xn)), it remains to
show that Wn,1 converges in probability to W1 := wE(σ
2
E + µ
2
E) +wR(σ
2
R + µ
2
R) +
wP (σ
2
P + µ
2
P ). Due to the independence of P and P˜, the expectation of Wn,1 with
respect to P× P˜ is given by
E
P×P˜
[Wn,1] = dn,·
1
n
(
nE(σ
2
E + µ
2
E) + nR(σ
2
R + µ
2
R) + nP (σ
2
P + µ
2
P )
)
.
It follows that the expectation E
P×P˜
[Wn,1] converges to W1. Let ε > 0 be an
arbitrary real number and n sufficiently large such that |E
P×P˜[Wn,1] −W1| < ε,
by applying Markov’s inequality, we obtain
(P× P˜) (|Wn,1 −W1| ≥ ε) ≤ 1(
ε− ∣∣E
P×P˜[Wn,1]−W1
∣∣)2 VarP×P˜ [Wn,1] .
To show that the right side converges to zero as n approaches infinity, we note
that for the sums dn,· :=
∑n
i=1 dn,i and
∑n
i=1 d
2
n,i, we have the asymptotic prop-
erties limn→∞ dn,· = 1 as well as limn→∞
∑n
i=1 d
2
n,i = 0. For both limits, we
took into account that none of the three groups vanish asymptotically, that is
limn→∞ nk/n = wk ∈ (0, 1). The variance of Wn,1 is equal to
Var
P×P˜[Wn,1] = EP [VarP˜[Wn,1]] + VarP [EP˜[Wn,1]] .
Since the forth moment of Xn,i with i = 1, . . . , n is bounded, for the second term
follows
VarP [EP˜[Wn,1]] = d
2
n,·VarP
[
1
n
n∑
i=1
X2n,i
]
≤ d2n,·
1
n
max
1≤i≤n
EP
[
X4n,i
]
.
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Hence, the variance VarP [EP˜[Wn,1]] converges to zero as n approaches infinity. It
remains to prove that EP [VarP˜[Wn,1]] converges to zero. Thereto, we calculate the
variance Var
P˜
[Wn,1]. With d¯n,· := dn,·/n, we obtain the variance VarP˜[Wn,1]
Var
P˜
[Wn,1] =
n∑
i=1
(dn,i − d¯n,·)2 1
n− 1
n∑
j=1
(
X2n,j −
1
n
n∑
i=1
X2n,i
)2
.
Since the forth moment of Xn,i with i = 1, . . . , n is bounded, the term
1
n− 1
n∑
j=1
(
X2n,j −
1
n
n∑
i=1
X2n,i
)2
converges in P-probability to a finite limit. Since
∑
i(dn,i−d¯n,·)2 converges to zero,
it follows that the expectation EP[VarP˜[Wn,1]] also converges to zero. Therefore,
Wn,1 converges in P× P˜-probability to W1.
4. With lim supn→∞(an + bn) ≤ lim supn→∞ an + lim supn→∞ bn and the algebraic
formula for the variance, we obtain P almost surly the inequality
lim
d→∞
lim sup
n→∞
1
n
n∑
i=1
(
Xn,i − X¯n,·
)2
1[d,∞)(|Xn,i − X¯n,·|)
≤ lim
d→∞
(
lim sup
n→∞
1
n
n∑
i=1
X2n,i1[d,∞)(|Xn,i − X¯n,·|) + lim sup
n→∞
(−X¯2n,·1[d,∞)(|Xn,i − X¯n,·|))
)
Since X¯n,· converges P almost surly to zero, the second limes superior is zero for
each d. Due to the strong law of large number which holds because the E[X2n,i]
are bounded, for each d, the first limes superior is equal to
lim sup
n→∞
1
n
n∑
i=1
X2n,i1[d,∞)(|Xn,i − X¯n,·|) =
∑
k=E,R,P
wkE
[
X2k,11[d,∞)(|Xk,1)
]
.
Since the expectation E[X2k,1] exists for k = E,R, P , the expectation E
[
X2k,11[d,∞)(|Xk,1|)
]
converges to zero as d approaches infinity.
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Figure 1: Level of significance αˆ of the Wald-type tests and the permutation test for
continuous data with equal group variances, σ2E = σ
2
R = σ
2
P = 1. The dashed grey lines
depict the area of α = 0.025 plus/minus two times the Monte-Carlo error.
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Figure 2: Level of significance αˆ of the Wald-type tests and the permutation test for
continuous data with unequal group variances σ2E = 1, σ
2
R = 2, σ
2
P = 3. The dashed
grey lines depict the area of α = 0.025 plus/minus two times the Monte-Carlo error.
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Figure 3: Significance level of the Wald-type tests and the permutation test for Poisson
data and negative binomial data. The dashed grey lines depict the area of α = 0.025
plus/minus two times the Monte-Carlo error.
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Figure 4: Level of significance of the studentized permutation test and the two Wald-
type tests against the total sample size n for the scenario (µE, µR, µP ) = (1.9, 1, 5.5)
with κ = 3 and sample size allocations 1:1:1. The dashed grey lines depict the target
significance level α = 0.025 plus/minus two times the Monte-Carlo error.
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